Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cell.2021.06.021 http://scihub22266oqcxt.onion/10.1016/j.cell.2021.06.021 34242577!8232969!34242577     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell 2021 ; 184 (16): 4203-4219.e32 Nephropedia Template TP {{tp|p=34242577|t=2021. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies |pdf=|usr=}}{{34242577}} gab.com Text In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies JO: Cell http://www.kidney.de/pget.php?&tw=1&pmid=34242577 #FOAvip SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) or the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-gamma (FcgammaR)-mediated enhancement of virus infection in vitro, while five non-neutralizing NTD antibodies mediated FcgammaR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo, increased lung inflammation can rarely occur in SARS-CoV-2 antibody-infused macaques. Twit Text FOAVip In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies ????Cell http://www.kidney.de/pget.php?&tw=1&pmid=34242577 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34242577 #FOAvip English Wikipedia <ref>{{Cite pmid|34242577}}</ref> In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies #MMPMID34242577 Li D; Edwards RJ; Manne K; Martinez DR; Schafer A; Alam SM; Wiehe K; Lu X; Parks R; Sutherland LL; Oguin TH 3rd; McDanal C; Perez LG; Mansouri K; Gobeil SMC; Janowska K; Stalls V; Kopp M; Cai F; Lee E; Foulger A; Hernandez GE; Sanzone A; Tilahun K; Jiang C; Tse LV; Bock KW; Minai M; Nagata BM; Cronin K; Gee-Lai V; Deyton M; Barr M; Von Holle T; Macintyre AN; Stover E; Feldman J; Hauser BM; Caradonna TM; Scobey TD; Rountree W; Wang Y; Moody MA; Cain DW; DeMarco CT; Denny TN; Woods CW; Petzold EW; Schmidt AG; Teng IT; Zhou T; Kwong PD; Mascola JR; Graham BS; Moore IN; Seder R; Andersen H; Lewis MG; Montefiori DC; Sempowski GD; Baric RS; Acharya P; Haynes BF; Saunders KO Cell 2021[Aug]; 184 (16): 4203-4219.e32 PMID34242577show ga SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) or the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-gamma (FcgammaR)-mediated enhancement of virus infection in vitro, while five non-neutralizing NTD antibodies mediated FcgammaR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo, increased lung inflammation can rarely occur in SARS-CoV-2 antibody-infused macaques. |Animals[MESH] |Antibodies, Neutralizing/*immunology[MESH] |Antibodies, Viral/immunology[MESH] |Bronchoalveolar Lavage Fluid/chemistry[MESH] |COVID-19/pathology/virology[MESH] |Cytokines/metabolism[MESH] |Female[MESH] |Haplorhini[MESH] |Humans[MESH] |Lung/pathology/virology[MESH] |Male[MESH] |Mice[MESH] |Mice, Inbred BALB C[MESH] |Protein Domains[MESH] |Receptors, IgG/metabolism[MESH] |SARS-CoV-2/isolation & purification/*physiology[MESH] |Spike Glycoprotein, Coronavirus/chemistry/*immunology[MESH] |Viral Load[MESH]In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and n(epmc).pdf DeepDyve Pubget Overpricing